| | ||||
| Transactions in Own Securities |
| |||
| | ||||
| 1 October 2024 | ||||
| | ||||
| Tate & Lyle plc (the "Company") announces that it has purchased the following number of its ordinary shares from Merrill Lynch International ("BofA") as part of its share buyback programme announced on 20 June 2024 (the "Programme"). | | |||
| | | | | |
| Date of purchase: | 1 October 2024 | | ||
| Number of ordinary shares of £0.2916666667 each purchased: | 177,021 | | ||
| Highest price paid per share (£): | 6.84 | | ||
| Lowest price paid per share (£) : | 6.75 | | ||
| Volume weighted average price paid per share (£): | 6.77 | | ||
| | | | | |
| The repurchased shares will be held in treasury. Following the purchase of these shares, the Company holds 15,656,454 of its ordinary shares in treasury and has 386,066,279 ordinary shares in issue (excluding treasury shares). | | |||
| | | | | |
| Aggregated Information |
| | | |
| | | | | |
| Date | Trading venue | Volume weighted average price (£ per share) | Number of Shares Purchased |
|
| 1 October 2024 | London Stock Exchange | 6.77 | 138,231 | |
| 1 October 2024 | Chi-X (CXE) | 6.78 | 29,656 | |
| 1 October 2024 | BATS (BXE) | 6.79 | 9,134 | |
| | | | | |
| Transaction Details |
| | | |
| | | | | |
| In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014 as it forms part of UK law, a full breakdown of the individual trades made by BofA on behalf of the Company as part of the Programme is detailed on the attached: | | |||
| http://www.rns-pdf.londonstockexchange.com/rns/5399G_1-2024-10-1.pdf | ||||
| | | | | |
| The LEI reference for Tate & Lyle PLC is 2138008K14474WPKZ244. | | | ||
| | | | | |
| For further information please contact: | | | | |
| | | | | |
| Christopher Marsh, VP, Investor Relations | | |||
| Mobile: +44 (0)7796 192 688 | | |||
| | | | | |
| Nick Hasell (FTI Consulting), Media Relations | | |||
| Mobile: +44 (0)7825 523 383 | | |||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
